Publisher
Springer Science and Business Media LLC
Subject
Organic Chemistry,General Pharmacology, Toxicology and Pharmaceutics
Reference95 articles.
1. Anastas JN, Moon RT (2013) WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 13(1):11–26
2. Arteaga CL, Truica CI (2004) Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer. Semin Oncol 31(1 Suppl 3):3–8
3. Azvolinsky A (2012) FDA approves enzalutamide (Xtandi) for late-stage prostate cancer. CancerNetwork. https://www.cancernetwork.com/articles/fda-approves-enzalutamide-xtandi-late-stage-prostate-cancer
4. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109(9):1721–1728
5. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS (2003) Molecular characterization of human prostate carcinoma cell lines. Prostate 57(3):205–225
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献